Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.
Eligibility
Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria:
* patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity \<10% with anti-ADAMTS13 antibodies detected);
* aged ≥ 18 years;
* male and female patients;
* treated with daratumumab for iTTP.
Exclusion Criteria:
* patients unwilling or unable to provide their informed consent;
* follow-up \< 6 months after daratumumab administration.
Primary outcome measure(s)
Proportion of responders to daratumumab — From the first daratumumab administration to 12 weeks after the last dose Number of patients responding to daratumumab / total number of patients treated with daratumumab (response defined as the achievement of ADAMTS13 activity levels above 20% of normal at any timepoint from the first daratumumab administration to 12 weeks after the last dose, without new additional immunosuppressants)
Trial sites (1)
Facility
City
Region
Status
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
Milan
Italy
Recruiting
More Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.